Program and Presentations

To view the program and presentations from the 5th Global Forum on TB Vaccines, click on the “Show Details” button for the sessions you wish to view. Please note that only presentations that the organizers have been given permission to share are posted on this page.

Click here to download the 5th Global Forum program and abstract book.

Tuesday 20 February 2018

10:30 – 12:15 Shahjehan

Opening Session

Co-Chairs: Danilo Casimiro, former Chief Scientific Officer, Aeras (USA) | Soumya Swaminathan, former Director-General, Indian Council of Medical Research (India) | David Lewinsohn, Chair, Stop TB Partnership Working Group on New TB Vaccines (USA) | Nick Drager, Executive Director, TuBerculosis Vaccine Initiative (Netherlands)

  • Overview of the TB epidemic globally and in India (video)
    Soumya Swaminathan, Deputy Director General of Programmes, World Health Organization (Switzerland)
  • Civil society perspective on the need for new TB vaccines (video)
    Blessina Kumar, Global Coalition of TB Activists (India)
  • Access and affordability for new TB vaccines (video)
    Hendrik Bekedam, World Health Organization (WHO) Representative to India, WHO Country Office (India)
  • The potential public health impact of new TB vaccines (video)
    Richard White, Professor, London School of Hygiene and Tropical Medicine and Director, TB Modelling and Analysis Consortium (UK)
  • Partnerships and collaboration in TB vaccine R&D (video)
    Renu Swarup, Senior Advisor, Department of Biotechnology, Ministry of Science & Technology (India)
  • India’s commitment to end TB (video)
    Sunil Khaparde, Deputy Director General (TB), Ministry of Health & Family Welfare, Government of India (India)
12:15 - 13:00 Shahjehan

Keynote Address


Why we need a vaccine to control TB and what we need to learn to develop an effective vaccine (video)
Barry Bloom, Joan L. and Julius H. Jacobson Research Professor of Public Health, Harvard University (USA)

13:00 – 14:00 Rani Bagh Lawn

Lunch

14:00 – 16:00 Shahjehan

Plenary Session 1: Increasing Probability of Success and Maximizing Impact

Co-Chairs: Ann Ginsberg, Aeras (USA) | Gagandeep Kang, Translational Health Science and Technology Institute (India)

 

16:15 - 17:45 Roshanara

Poster Discussion 1: Basic Vaccine Concepts and Correlates of Protective Immunity

Coffee/tea to be served in the session rooms

Facilitators: David Lewinsohn, Oregon Health & Science University (USA) | Vinay Kumar Nandicoori, National Institute of Immunology (India)

  • Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) exacerbates TB infection after aerosol challenge in mice – implications for host-directed therapy
    Rasmus Mortensen, Statens Serum Institute (Denmark)
  • Deciphering the role of VapBC TA modules in virulence and pathogenesis of Mycobacterium tuberculosis
    Sakshi Agarwal, Translational Health Science and Technology Institute (India)
  • Mycobacterium tuberculosis hbhA and mtp deletion elicits unique canonical pathways during early infection in THP-1 differentiated macrophages
    Suventha Moodley, University of KwaZula-Natal (South Africa)
  • Targeting ClpB abrogates stress tolerance in Mycobacterium tuberculosis and hence its growth and infectivity
    Prajna Tripathi, National Institute of Immunology (India)
  • Circulating HLA-DR+IFNγhiIL-17hiCD4+T effectors resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis
    Asma Ahmed, Indian Institute of Science (India)
  • PPM, a novel Mycobacterium tuberculosis (Mtb) antigen: a candidate for vaccine development to prevent progression to tuberculosis
    Chaouki Benabdessalem, Institut Pasteur de Tunis (Tunisia)
  • Evaluation of the immunogenicity of a promising vaccine regime to identify immune correlates of protection
    Nawamin Pinpathomrat, University of Oxford (UK)
  • Demonstration of a correlation between the in vitro direct mycobacterial growth inhibition assay (MGIA) and protection from in vivo mycobacterial challenge
    Rachel Tanner, University of Oxford (UK)
  • Altered systemic levels of neutrophil and mast cell granular proteins in tuberculosis-diabetes co-morbidity and changes following treatment
    Kadar Abbas Moideen, National Institute of Health-NIRT-International Center for Excellence in Research (India)
Sheesh Mahal

Poster Discussion 2: Diagnostics and Epidemiology

Facilitators: Hazel Dockrell, London School of Hygiene and Tropical Medicine (UK) | Jaya Tyagi, Department of Biotechnology, All India Institute of Medical Sciences (India)

  • BCG vaccine as proof-of-concept
    Marcel Behr, McGill University (Canada)
  • Effect of anti-tuberculosis treatment on the systemic levels of matrix metalloproteinases and tissue inhibitors of MMP in tuberculosis – diabetes co-morbidity
    Nathella Pavan Kumar, NIH-ICER-NIRT (India)
  • The ESAT-6 free IGRA, a companion diagnostic for ESAT-6 based TB vaccines
    Morten Ruhwald, Statens Serum Institut (Denmark)
  • Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T-cells differentiate latent from active tuberculosis
    Srabanti Rakshit, Indian Institute of Science (India)
  • Proliferative T cell (CD3+Ki67+) response to PPD and M. tuberculosis cell membrane complements the tuberculin skin test for detection of latent TB infection in healthy North Indian hospital contacts 
    Sudhir Sinha, Sanjay Gandhi Post-graduate Institute of Medical Sciences (India)
  • CD14+ CD16+ cells as immunological marker for protection in house hold contacts with latent tuberculosis infection
    Venkata Sanjeev Kumar Neela, Bhagwan Mahavir Medical Research Centre (India)
  • Optimization and interpretation of serial QuantiFERON testing to measure acquisition of M. tuberculosis infection
    Elisa Nemes, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • Updating the recommended age of BCG vaccination? Modelling the potential impact on global paediatric TB mortality
    Partho Roy, London School of Hygiene and Tropical Medicine (UK)
    Presented by Rebecca Harris, London School of Hygiene and Tropical Medicine (UK)
  • Do we have identified target groups and a population based strategy for vaccination against tuberculosis to cut down transmission?
    U.D. Gupta, National JALMA Institute for Leprosy and Other Mycobacterial Diseases (India)
  • TB infection among household contacts: Preventive therapy for all?
    Chandra Kumar Dolla, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital (India)
  • Infection free “resistors” among household contacts of culture-confirmed adult pulmonary TB cases
    Vidya Mave, Byramjee Jeejeebhoy Government Medical College – Johns Hopkins University Clinical Research Site (India)
  • Incidence of Mycobacterium tuberculosis infection among household contacts of adult pulmonary tuberculosis cases in India
    Mandar Paradkar, Byramjee Jeejeebhoy Government Medical College Clinical Research Site (India)
Mumtaz Mahal

Poster Viewing: Novel Vaccine Concepts; Chemistry, Manufacturing and Controls

Novel Vaccine Concepts

  • The impact of previous BCG vaccination in enhancing the effectiveness of tuberculosis drugs to control mycobacterial growth ex-vivo
    Satria Arief Prabowo, London School of Hygiene and Tropical Medicine (UK)
  • The role of DPP4 and antagonist CXCL10 in the pathogenesis of TB, an opportunity for vaccines and HDT?
    Morten Ruhwald, Statens Serum Institut (Denmark)
  • Mycobacterium tuberculosis H37Rv cell wall isolated poly L-glutamines as novel Th1-biased adjuvant
    Manish Gupta, Jawaharlal Nehru University (India)
  • De novo arginine biosynthesis pathway of Mycobacterium tuberculosis: A novel drug target and potential vaccine candidate
    Sangeeta Tiwari, Albert Einstein College of Medicine (USA)
  • Epitope-based vaccine design for Mycobacterium tuberculosis strains through pan-genomic reverse vaccinology
    Ravina Madhulitha Nalamolu, Sri Venkateswara Institute of Medical Sciences University (India)
  • Development of a recombinant BCG vaccine expressing a monomeric form of ESAT-6
    Makram Essafi, Institut Pasteur de Tunis (Tunisia)
  • Insights into mycobacterial membrane vesicles: a potential subunit vaccine candidate
    Praapti Jayaswal, Translational Health Science and Technology Institute (India)
  • Assessment of the protective effect, against tuberculosis, of a new vaccine composition
    Rania Bouzeyen, Insitut Pasteur de Tunis (Tunisia)
  • Assessing the immunological activity of the fusion protein consisted of the major secretory protein of Mycobacterium tuberculosis
    Hyun Shik Bae, Chungnam National University (South Korea)
  • Synthetic polysaccharide conjugate vaccines expressing Mycobacterium tuberculosis antigens induce high-titer antibody responses in mice, guinea pigs, and rabbits
    Dominick Laddy, Aeras (USA)
  • Rv2882c-Rv20xxc, a novel immunostimulatory antigen of Mycobacterium tuberculosis, activates bone-marrow derived dendritic cell
    Ki-Won Shin, College of Medicine, Chungnam National University (South Korea)
  • Mycobacterium tuberculosis protein Rv2299c fused-ESAT-6 subunit vaccine confers improved protection against the hypervirulent strain HN878 in mice
    Seunga Choi, College of Medicine, Chungnam National University (South Korea)
  • Evaluation of attenuated strains as auxotrophic vaccines against Mycobacterium tuberculosis
    Tannu Priya Gosain, Translational Health Science and Technology Institute (India)

Chemistry, Manufacturing and Controls

  • Miniaturized fluorescence adapter for fluorescence sputum smear microscopy using bright-field microscope
    Mamta Rani, IIT Delhi (India)
    Presented by Pooja Singh, IIT Delhi (India)
  • Development of an innovative, rapid, affordable and automated system for selective enrichment, isolation and detection of MTB in sputum sample
    Saumya Singh, IIT Delhi (India)
  • Comparison of pellicle and liquid grown BCG reference strains in standard BCG batch release assays and protection studies
    Megan Fitzpatrick, Aeras (USA)

17:45 - 18:30 Rani Bagh Lawn

Networking and Refreshments

18:30 - 20:00 Shahjehan

Inaugural Ceremony

Co-Chairs: Nick Drager, Executive Director, TuBerculosis Vaccine Initiate (Netherlands) | Lucica Ditiu, Executive Director, Stop TB Partnership (Switzerland)

  • Prevention is better than cure: A survivor story (video)
    Mona Balani, Touched by TB (India)
  • Regional efforts to bending the curve (video)
    Poonam Khetrapal Singh, WHO Regional Director for South-East Asia (India)
  • Translating rhetoric into action: Transforming the global TB response (video)
    Soumya Swaminathan Deputy Director General of Programmes, World Health Organization (Switzerland)
  • Research, innovation and partnership as the pathway to success (video)
    Ashutosh Sharma, Secretary, Department of Biotechnology and Department of Science and Technology, Ministry of Science & Technology (India)
  • India’s role in TB vaccine research (video)
    Preeti Sudan, Secretary, Department of Health and Family Welfare, Government of India & Secretary, Department of Health Researcher & Director-General, Indian Council of Medical Research
  • India’s mission to strengthen vaccine research (video)
    Anupriya Patel, Honourable Minister of State, Ministry of Health & Family Welfare (India)
20:00 - 21:30 Rani Bagh Lawn

Forum Dinner

Wednesday, 21 February 2018

9:00 - 11:00 Shahjehan

Plenary Session 2: Clinical Development of New TB Vaccines

Co-Chairs: Souleymane Mboup, Institut de Recherche en Santé, de Surveillance Epidemiologique et de Formations (Senegal) | Sanjay Mehendale, Indian Council of Medical Research (India)

11:00 - 11:30

Coffee/Tea Break

11:30 - 13:00 Shahjehan

Breakout Session 1: Basic Science Research

Co-chairs: Katrin Eichelberg, National Institute for Allergy and Infectious Diseases (USA) | Rajesh Gohale, National Institute of Immunology (India)

Jehangir

Breakout Session 2: Clinical Research

Co-chairs: Sanjay Gurunathan, Sanofi Pasteur (USA) | Randeep Guleria, All India Institute of Medical Sciences (India)

13:00 - 14:00 Rani Bagh Lawn

Lunch

14:00 - 16:00 Shahjehan

Plenary Session 3: Novel Approaches to TB Vaccine Research & Development

Co-chairs: JoAnne Flynn, University of Pittsburgh (USA) | Anil Tyagi, Guru Gobind Singh Indraprastha University (India)

  • The route of BCG vaccination determines immunity and protection against Mycobacterium tuberculosis infection in non-human primates
    Robert Seder, National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA)
  • Vaccination following mycobacterial exposure
    Thomas Scriba, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • Cytomegalovirus (CMV)-based TB vaccines 
    Aurelio Bonavia, Vir Biotechnology (USA)
  • Nucleic acid vaccines for tuberculosis
    Jeffrey Ulmer, GSK Vaccines (USA)
  • Protective potential of Mycobacterium indicus pranni (MIP) and the underlying mechanisms in animal models of tuberculosis
    Sangeeta Bhaskar, National Institute of Immunology (India)
16:00 - 16:30

Coffee/Tea Break

16:30 - 18:00 Roshanara

Poster Discussion 3: Preclinical Research

Facilitators: Damilo Casimiro, former Aeras (USA) | Sarala Balachandran, Council of Scientific and Industrial Research (India)

  • Early and local immune mechanisms of TB disease progression and control upon ultra-low dose infection in rhesus versus cynomolgus macaques
    Karin Djikman, Biomedical Primate Research Centre (Netherlands)
  • Experimental evaluation of a novel microneedle device for BCG vaccination
    Jungho Kim, International Tuberculosis Research Center (South Korea)
    Presented by Jake Whang, International Tuberculosis Research Center (South Korea)
  • Role of BCG encapsulated alginate particles in activation of bone marrow derived dendritic cells for providing better immune response against TB
    Ashwani Kesarwani, National Institute of Immunology; Jamia Handard (India)
  • bioA mutant of Mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs
    Ritika Kar Bahal, University of Delhi South Campus (India)
  • Animal dose response curve predicts lower optimal tuberculosis vaccine dose in humans: The use of vaccine Immunostimulation/ Immunodynamic modelling methods to inform vaccine dose decision-making
    Sophie Rhodes, London School of Hygiene and Tropical Medicine (UK)
    Presented by Richard White, London School of Hygiene and Tropical Medicine (UK)
  • T cell immunity in the lung and protection following aerosol, intravenous, or intradermal administration of BCG in nonhuman primates
    Patricia Darrah, National Institute of Immunology and Infectious Diseases, National Institutes of Health (USA)
  • A recombinant BCG-LTAK63 strain induces increased innate and long-term immunity correlating with enhanced protection against tuberculosis
    Luciana Leite, Instituto Butantan (Brazil)
  • Recombinant BCG-LTAK63 strain induces lower immunopathological effects and superior protection against tuberculosis in BALB/c and C57BL/6 mice
    Carina Santos, Instituto Butantan (Brazil)
  • Intransal vaccination with Mycobacterium indicus pranii leads to infiltration of protective memory T-cells in lung airway lumen
    Ananya Gupta, National Institute of Immunology (India)
  • Boosting with recombinant MVA expressing α-crystallin antigen of M. tuberculosis augments the protection imparted by BCG against tuberculosis in guinea pigs
    Prachi Nangpal, University of Delhi South Campus (India)
  • A single dose nanoparticulate vaccine approach against tuberculosis
    Manish Gupta, Jawaharlal Nehru University (India)
  • Passive vaccination with human IgA protects against MDR-TB infection in mice
    Andy Tran, St. George’s University of London (UK)
Sheesh Mahal

Poster Discussion 4: Clinical Research and Community Engagement

Facilitators: Souleymane Mboup, Institut de Recherche en Sante, de Surveillance Epidemiologique et de Formations (Senegal) | Lorraine Misquith, Lawyers Collective; Global Coalition of TB Activists (India)

  • Immunogenicity of AERAS-404 or BCG revaccination in a prevention of established M. tuberculosis infection efficacy trial
    Virginie Rozot, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • Phase 1 clinical trial to evaluate the safety and immunogenicity of an adenovirus-based tuberculosis vaccine (Ad5Ag85A) administered by aerosol to healthy volunteers
    Fiona Smaill, McMaster University (Canada)
  • Dose definition of the novel TB vaccine ID93 + GLA-SE for TB endemic countries
    Adam Penn-Nicholson, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • The Toll-like receptor 4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine
    Tracey Ann Day, Infectious Disease Research Institute (USA)
  • Safety and immunogenicity of H56:IC31 in HIV negative adults with and without latent tuberculosis(TB) infection
    Angelique Kany Kany Luabeya, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • Impact of implementing an effective community engagement strategy on retention rates in a Phase 2b TB disease prevention vaccine trial in South Africa, Zambia, and Kenya
    Anja van der Westhuizen, Aeras Africa (South Africa)
  • Building a portfolio of community engagement projects to enhance TB
    Michele Tameris, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • Drama as a community engagement tool to raise TB awareness
    Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • Leveraging libraries to raise awareness about TB on World TB Day
    Kelvin Vollenhoven, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • Using eCompliance for tracking patients and ensuring accuracy of data in vaccine trials
    Shelly Batra, Operation ASHA (India)
Mumtaz Mahal

Poster Viewing: Basic Science Research, Biomarkers and Correlates, Epidemiology

Basic Science Research; Biomarkers and Correlates of Immunity and Protection

  • Functional, antigen-specific stem cell-like memory (Tscm) CD4+ T cells are induced by human Mycobacterium tuberculosis infection
    Cheleka Anne-Marie Mpande, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • Activation of L-type voltage gated calcium channel in macrophages suppresses protective responses during Mycobacterium tuberculosis infection
    Deepika Sharma, University of Delhi (India)
  • Role of phosphorylation on secretion in Mycobacterium tuberculosis and its impact on its survival
    Basanti Malakar, National Institute of Immunology (India)
  • Challenges in detecting TB drug resistance in a field setting in Southwestern Uganda
    Patrick Orikiriza, Mbarara University of Science and Technology  (Uganda)
  • Calcimycin induced autophagy decreases mycobacterial growth in THP-1 cells through P2RX7 dependent pathway mediated by intracellular calcium
    Shradha Mawatwal, National Institute of Technology, Rourkela (India)
  • Phenotypic adaptation to drug treatment in Mycobacterium tuberculosis is mediated by DNA gyrase
    Eira Choudhary, Translational Health and Science Technology Institute (India)
  • Assessment of anti-mycobacterial activity of some selected Congolese medicinal plants
    Gedeon Ngiala Bongo, University of Kinshasa (Democratic Republic of Congo)
  • Various aspects of GTPases towards its essentiality in survival and pathogenesis of Mycobacterium tuberculosis H37Rv
    Shivangi, CSIR-Institute of Genomics and Integrative Biology (India)
  • Cytokines, matrix metalloproteinases, angiogenic factors and acute phase proteins as biomarkers in tuberculous lymphadenitis
    Gokul Raj Kathamuthu, National Institute for Research in Tuberculosis (NIRT)-NIH-ICER (India)
  • Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis
    Hyejon Lee, Yonsei University College of Medicine (South Korea)
    Presented by Bora Sim, Yonsei University College of Medicine (South Korea)

Epidemiology

  • Sputum sample collection for diagnosis of pediatric pulmonary tuberculosis, does method and site of sample collection matter?
    Willy Ssengooba, Makerere University (Uganda)
  • Tuberculosis massive active case discovery in East Jakarta 2016-2017: the role of Ketuk Pintu Layani Dengan Hati (KPLDH) and Juru Pemantau Batuk (Jumantuk) cadre programs
    Ngabila Salama, East Jakarta Health Office (Indonesia)
  • Clinical Profile Of tuberculous meningitis in a tertiary care center in India
    Anita Basavaraj, BJGMC (India)
18:00 - 20:00 Shahjehan, Mumtaz Mehal, Sheesh Mahal, and Roshanara

Networking Reception and Poster Viewing

Cultural performance followed by networking and poster viewing
Posters on display in Mumtaz Mahal, Sheesh Mahal, and Roshanara
Food and drink stations will be located in Shahjehan and Roshanara

Thursday, 22 February 2018

7:15 - 8:45 Jenhangir

Satellite Session: Panel Discussion and Audience Q&A on the H4:IC31®/BCG Revaccination POI Trial Results

Organized by Sanofi Pasteur and Aeras

Panel discussion featuring:

  • Ann Ginsberg, Aeras, USA (moderator)
  • Gavin Churchyard, Aurum Institute (South Africa)
  • Carl Dieffenbach, National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA)
  • Mark Hatherill, South African Tuberculosis Vaccine Initiative, University of Cape Town (South Africa)
  • Sanjay Gurunathan, Sanofi Pasteur (USA)

Click here to view the video of the session

9:00 - 11:00 Shahjehan

Plenary Session 4: The Cutting Edge: Translating Scientific Advances into New TB Vaccines

Co-Chairs: Peter Andersen, Statens Serum Institute (Denmark) | G.P. Talwar, Talwar Research Foundation (India)

11:00 - 11:30

Coffee/Tea Break

11:30 - 13:00 Shahjehan

Breakout Session 3: Novel Vaccine Concepts and Preclinical Research

Co-Chairs: Luciana Leite, Instituto Butantan (Brazil) | Seyed E. Hasnain, Jamia Hamdard (India)

11:30 - 13:00 Jehangir

Breakout Session 4: Biomarkers, Correlates, and Epidemiology

Co-Chairs: Gerald Voss, TuBerculosis Vaccine Initiative (Belgium) | Vijaya Lakshmi Valluri, Bhagwan Mahavir Medical Research Center (India)

13:00 - 14:00 Rani Bagh Lawn

Lunch

14:00 - 16:30 Shahjehan

Plenary Session 5: Partnering for Progress and Innovation

Co-Chairs/Facilitators: Ole Olesen, European & Developing Countries Clinical Trials Partnership (Netherlands) | Renu Swarup, Biotechnology Industry Research Assistance Council; Department of Biotechnology (India)

Roundtable discussion featuring:

  • Fareed Abdullah, South African Medical Research Council (South Africa)
  • Shelly Batra, Operation ASHA (India)
  • Michel Kazatchkine, Global Health Centre, Graduate Institute for International Development Studies (Switzerland)
  • Rajiv I. Modi, Chairman of the Confederation of Industry National Council on Pharmaceuticals;  Cadila Pharmaceuticals (India)
  • Jacqueline Shea, Aeras (USA)

Closing Session


Co-Chairs: Danilo Casimiro, former Aeras (USA) |  David Lewinsohn, Stop TB Partnership Working Group on New Vaccines (USA) | Nick Drager, Tuberculosis Vaccine Initiative (Netherlands)

Closing Address (video)
Lucica Ditiu, Stop TB Partnership (Switzerland)

Friday, 23 February 2018

Site Visits

Site visits to four local institutions involved in  TB research and care are offered to 5th Global Forum delegates.

8:30 – 12:00     Operation ASHA
8:30 – 14:00     Translational Health Science and Technology Institute
9:00 – 11:30      International Centre for Genetic Engineering and Biotechnology
9:30 – 13:00     National Institute for Tuberculosis and Respiratory Diseases

Please visit the Site Visits page for more information.

Click here to view the 5th Global Forum program-at-a-glance.

Click here to download the session program

Click here to download the poster program

Sign up for email announcements or follow us on Twitter for program updates.